Feds scold Novartis for Exelon promos

Are the FDA's marketing specialists growing harder noses? First, Pfizer was scolded for its "misleading" Geodon advertising. Now, the FDA is shaking its finger at Novartis over promotional materials that claim its Alzheimer's drug Exelon is more efficacious than Pfizer's Aricept, and downplays its side effects, too. The FDA questions both claims and demands that Novartis stop using the materials, which are targeted at healthcare professionals.

In Pfizer's case, the FDA questioned a medical journal ad that left out the potential for serious side effects--such as diabetes and neurological disorders--from Geodon, a schizophrenia remedy. The company also claimed Geodon is better than competitor Haloperidol IM, but the FDA says neither evidence nor clinical experience has proven so. Both companies say they'll comply with the FDA's orders.

- check out the warning letter for Exelon
- read the report from PharmaTimes
- and here's the report from CNN

Related Articles:
FDA OKs Novartis' Exelon for dementia. Report
New studies support use of Exelon patch. Report
AMA to study the impact of drug advertising. Report
NCI cancels Novartis cancer study. Report
Australia bans Novartis' Prexige. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.